VREXHealthcare · Medical DevicesThe 3 Wall Street analysts covering Varex Imaging Corp. hold a median 12-month price target of $19 — +2.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Varex Imaging Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Volatility (20): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VREX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | CJS Securities | Downgrade | Market Perform | — |
| 11 Aug 2026 | Oppenheimer | Downgrade | Perform | — |
| 10 Aug 2026 | Sidoti & Co. | Downgrade | Neutral | $19 |
| 19 Nov 2025 | B. Riley Securities | Reiterates | Buy | — |
| 19 Nov 2025 | B. Riley Securities | Reiterates | Buy | $16 |
| 19 Nov 2025 | Oppenheimer | Maintains | Outperform | $23 → $18 |
| 19 Nov 2025 | Oppenheimer | Maintains | Outperform | — |
| 8 Aug 2025 | B. Riley Securities | Maintains | Buy | — |
| 7 Feb 2025 | B. Riley Securities | Reiterates | Buy | — |
| 7 Feb 2025 | Oppenheimer | Maintains | Outperform | — |
| 23 Aug 2024 | B. Riley Securities | Initiates | Buy | — |
| 15 Nov 2023 | Oppenheimer | Maintains | Outperform | — |
| 2 Aug 2023 | Oppenheimer | Reiterates | Outperform | — |
| 24 May 2023 | Jefferies | Maintains | Hold | — |
| 12 Oct 2022 | Jefferies | Initiates | Hold | — |
| 5 Feb 2021 | Oppenheimer | Upgrade | Outperform | — |
| 13 Aug 2020 | Oppenheimer | Downgrade | Perform | — |
| 13 May 2020 | Jefferies | Maintains | Hold | — |
| 13 May 2020 | JP Morgan | Downgrade | Neutral | — |
| 13 May 2020 | Sidoti & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VREX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Varex Imaging Corp. returned +55.5% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 70% of US stocks
Cheaper than 51% of US stocks
Cheaper than 35% of US stocks
Higher than 36% of US stocks
Higher than 44% of US stocks
Higher than 65% of US stocks
Higher than 53% of US stocks
Higher than 53% of US stocks
Higher than 72% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Varex Imaging Corp. has a market value of $782.6M and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $865.0M. The latest quarter grew 3.7% year on year.
Net income over the same four quarters: $22.5M, a 2.6% net margin.
Diluted earnings per share, trailing twelve months: $0.52.
Free cash flow in the twelve months to 30 June 2026: −$20.2M.
Trailing P/E: 34.8×; forward P/E: 17.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Varex Imaging Corp. employs 2,500 people — $346K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Varex Imaging Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Varex Imaging stockholders approved the proposed merger with Teledyne Technologies at a special meeting, clearing a key shareholder-vote requirement.
Why it matters — VREX watchers may note that shareholder approval advances the proposed transaction by satisfying a key voting requirement.
The law firm Kahn Swick & Foti, and former Louisiana Attorney General Charles C. Foti Jr., are investigating the proposed sale of Varex Imaging Corporation to Teledyne Technologies. Under the proposed terms, Varex shareholders would receive $18.90 in cash per share, and KSF is examining whether this consideration and the sale process are adequate.
Why it matters — Varex watchers would care because the investigation raises questions about whether the $18.90-per-share consideration in the proposed sale adequately values the company, which could affect the deal's outcome.
Halper Sadeh LLC, an investor rights law firm, announced it is investigating whether Varex Imaging Corporation obtained a fair price for its shareholders in its sale to Teledyne Technologies for $18.90 per share in cash. The firm is encouraging Varex shareholders to learn about their rights and options regarding the transaction.
Why it matters — The investigation raises questions about the fairness of the acquisition price for VREX shareholders and could signal potential legal scrutiny of the sale terms.
Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations involving Varex Imaging Corporation and several other companies, inviting shareholders to contact the firm at no cost to discuss the investigations.
Why it matters — A VREX watcher would want to monitor the investigation as it could relate to potential shareholder concerns regarding the company.
Zacks Investment Research published an article asking whether value investors should buy Varex Imaging (VREX) stock, explaining that the firm's approach combines its Zacks Rank system with value, growth, and momentum trends.
Why it matters — VREX watchers would care because this coverage highlights how the company is being evaluated for value-investing potential within Zacks' screening framework.
The 3 Wall Street analysts covering Varex Imaging Corp. have a median 12-month price target of $19, with estimates ranging from $19 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Varex Imaging Corp., 0 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Varex Imaging Corp. 81 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Varex Imaging Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +2.6% from the last close, and Ticker Nerd's factor model ranks Varex Imaging Corp. 81 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Varex Imaging Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VREX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $19 over the next 12 months.
Varex Imaging Corp. returned +55.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Varex Imaging Corp. is a medical technology company that designs, manufactures, sells, and services X-ray imaging components and related systems.
The most recent item we track (MarketBeat, 29 Oct 2026): "Varex Imaging Shareholders Approve Teledyne Merger Agreement". Varex Imaging stockholders approved the proposed merger with Teledyne Technologies at a special meeting, clearing a key shareholder-vote requirement.
Varex Imaging Corp. is a medical technology company that designs, manufactures, sells, and services X-ray imaging components and related systems. Varex Imaging Corp. serves two main business segments: Medical and Industrial. Its Medical segment supplies X-ray tubes, digital detectors, high-voltage connectors, image-processing software, workstations, and other components used in applications such as computed tomography, mammography, oncology, and general diagnostic imaging. Its Industrial segment provides X-ray accelerators, detectors, and inspection solutions for security screening, cargo inspection, and non-destructive testing. The company works primarily with original equipment manufacturers, independent service providers, distributors, and end users that integrate its products into imaging platforms. Headquartered in Salt Lake City, Utah, Varex Imaging Corp. plays a specialized role in the global imaging supply chain by providing critical technologies used to detect, diagnose, protect, and inspect across medical, industrial, and security markets.
CEO Mr. Sunny S. Sanyal · 2,500 employees · United States · https://www.vareximaging.com
